Antibodies hit drug-resistant cancer cells to improve durability of targeted therapies
Scientists at the Perlmutter Cancer Center at New York University Langone Health have created antibodies designed to target and kill cells that develop resistance to targeted therapies, thereby tackling a barrier to durable anticancer effects. Read More
Conferences
Science Briefs
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
